In:
The FEBS Journal, Wiley, Vol. 289, No. 5 ( 2022-03), p. 1276-1301
Abstract:
The molecular characterization of mechanisms underlying transcriptional control and epigenetic inheritance since the 1990s has paved the way for the development of targeted therapies that modulate these pathways. In the past two decades, cancer genome sequencing approaches have uncovered a plethora of mutations in chromatin modifying enzymes across tumor types, and systematic genetic screens have identified many of these proteins as specific vulnerabilities in certain cancers. Now is the time when many of these basic and translational efforts start to bear fruit and more and more chromatin‐targeting drugs are entering the clinic. At the same time, novel pharmacological approaches harbor the potential to modulate chromatin in unprecedented fashion, thus generating entirely novel opportunities. Here, we review the current status of chromatin targets in oncology and describe a vision for the epigenome‐modulating drugs of the future.
Type of Medium:
Online Resource
ISSN:
1742-464X
,
1742-4658
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
2172518-4
SSG:
12
